Video Experimental Relacionado
Updated: Aug 25, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
El dipiridamolo y otros inhibidores de la fosfodiesterasa actúan como agentes antitrombóticos al potenciar la
Lancet (London, England)
|June 17, 1978
Resumen
Los efectos antitrombóticos del dipyridamole se mejoran con dosis bajas de aspirina, pero se bloquean con dosis altas de aspirina. Esta es la combinación de esta combinación.
Área de la Ciencia:
- Farmacología Farmacología.
- Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular
- La trombosis es una trombosis.
Sus antecedentes:
- El dipiridamolo ejerce efectos antitrombóticos a través de la inhibición de la fosfodiesterasa, potenciada por la AMP cíclica plaquetaria estimulada por prostaciclina.
- El efecto de la aspirina sobre la función plaquetaria es dependiente de la dosis, influyendo en la actividad de la ciclooxigenasa y la formación de prostaciclinas.
Objetivo del estudio:
- Para investigar la interacción dependiente de la dosis entre la aspirina y el dipiridamolo en la actividad antitrombótica.
- Para dilucidar los mecanismos subyacentes a la potenciación o inhibición de los efectos del dipiridamolo por la aspirina.
Principales métodos:
- Evaluación de los efectos antitrombóticos del dipyridamole solo y en combinación con dosis variables de aspirina.
- Evaluación de los niveles cíclicos plaquetarios de AMP y la formación de prostaciclina en respuesta a las combinaciones de fármacos.
Principales resultados:
- La aspirina en dosis bajas inhibe selectivamente la ciclooxigenasa plaquetaria, potenciando los efectos antitrombóticos del dipiridamolo.
- Las dosis altas de aspirina inhiben la formación de prostaciclina, eliminando así los efectos antitrombóticos del dipiridamolo.
- Potenciación de la teofilina observada con dosis bajas de aspirina y dipiridamolo.
Conclusiones:
- La eficacia antitrombótica de la combinación de aspirina y dipiridamolo es críticamente dependiente de la dosis de aspirina.
- La selección cuidadosa de la dosis es esencial para lograr efectos antitrombóticos sinérgicos y evitar el antagonismo.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...